A Phase 2 Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Conditions

Cervix

Phase II

Volunteers
Health Professionals

What is the purpose of this trial?

The primary objective of the study is to estimate the clinical benefit of cemiplimab + ISA101b after progression on first line chemotherapy, as assessed by objective response rate (ORR).

Ages
18 years and older
Gender
Female only

Find out more about who can participate in this trial

Trial with
Regeneron Pharmaceuticals, Inc.
Start Date
03/29/2022
End Date
10/22/2024

For more information about this study, contact:

Lisa Baker

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Alessandro Santin, MD
Professor of Obstetrics, Gynecology, and Reproductive Sciences; Disease Aligned Research Team Leader, Gynecologic Oncology Program, Yale Cancer Center; Co-Chief, Section of Gynecologic Oncology

Sub-Investigators

Last Updated
04/01/2022
Study HIC
#2000029247

A Phase 2 Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information